Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
公司代碼AGMB
公司名稱Agomab Therapeutics NV
上市日期Feb 06, 2026
CEOKnotnerus (Tim)
員工數量- -
證券類型Depository Receipt
年結日Feb 06
公司地址Posthoflei 1/6
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Belgium
郵編2600
電話
網址https://agomab.com/
公司代碼AGMB
上市日期Feb 06, 2026
CEOKnotnerus (Tim)